Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Endexx Applauds Recent Judgement in European Hemp Law

EDXC

“CBD is a Non-Narcotic”

CAVE CREEK, AZ, Nov. 30, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire Endexx Corporation, (OTC: EDXC) (the “Company” or a/k/a “CBD Unlimited”), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products is pleased to share that in Europe, CBD has just been declared a “non-narcotic substance” by European Court paving the way for world changes and explosive global CBD sales growth.

Hemp Industry Daily reports: “European Union’s high court said Thursday that CBD derived from the entire hemp plant is not a narcotic under any international drug treaty and is therefore subject to EU law on the free movement of goods among member states. The landmark interpretation of the 1961 U.N. Single Convention on Narcotic Drugs, handed down by five judges at the EU Court of Justice in Luxembourg, sets a precedent for the regulation of hemp-derived CBD products in Europe and could lead to a shift in how CBD extracts are produced.”

Endexx, under its flagship brand, CBD Unlimited, believes this major change will affect Endexx’s global and domestic business enterprise in the following two key ways:

1) We have Global Distributors throughout the world ready to distribute our CBD products and with these new industry changes, our product sales are projected to reach a global consumer base and can grow 10-25X current projections.

2) We believe the European law ruling will allow the US Congress to advance their new guidance and laws, making CBD fully compliant and legal domestically and globally. The US interprets European law similarly in approach to standardized agriculture crop policy. This ruling opens the potential for banking, insurance, and commodity trading industries to build infrastructure for long term success.

For Endexx, a “Pioneer” and one of the first CBD companies in the market, we believe this to be a watershed moment. Our shareholders and management will look back on this day as a milestone changing the industry forever.

Endexx, CEO, Todd Davis added, “These new changes will enhance our global directive for manufacturing and distribution of finished goods, as well as, expanding opportunities here in the US. We have positioned ourselves to quickly adapt and take advantage of these rapidly occurring market changes.” Davis added, “this is the first known ruling of CBD from the Whole Hemp plant in regards to the 1961 United Nations Law. Subsequently, all International countries that comply with this law, can now interpret the law in kind.”

Reference(s):

https://curia.europa.eu/jcms/upload/docs/application/pdf/2020-11/cp200141en.pdf

https://www.cov.com/en/news-and-insights/insights/2020/11/cjeu-confirms-that-cbd-is-not-a-narcotic-drug

About Endexx Corporation and CBD Unlimited

Endexx Corporation, through its operating subsidiary CBD Unlimited, Inc., develops and distributes all-natural CBD products derived from the Cannabis Sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work in order to protect the accuracy in dosage and delivery of absorption per each serving.

Safe Harbor Notice

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief, or current expectations of the company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions, and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

Contact:
For further investor and media information, please contact:
Endexx Corporation
Todd Davis, Chairman, and CEO
endexx@endexx.com
480-595-6900


Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today